Reflection and ReactionSecondary prevention of stroke: can we do better than aspirin?
References (11)
- et al.
Cilostazol Stroke Prevention Study: a placebo controlled double blind trial for secondary prevention of cerebral infarction
J Stroke Cerebrovasc Dis
(2000) - et al.
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study
Lancet Neurol
(2008) - et al.
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
Am Heart J
(2009) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
BMJ
(2002)- et al.
Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin
J Neurol Neurosurg Psychiatry
(1999)
There are more references available in the full text version of this article.
Cited by (6)
Platelets and diabetes
2017, Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: an UpdatePharmacodynamic properties of antiplatelet agents: Current knowledge and future perspectives
2012, Expert Review of Clinical PharmacologyPotassium channels as a target in smooth muscles and nerves
2012, Potassium Channels as a Target for Clinical TherapeuticsThe evolution of antiplatelet therapy in cardiovascular disease
2011, Nature Reviews Cardiology
Copyright © 2010 Elsevier Ltd. All rights reserved.